Moderna Q2 preview: Where next for MRNA stock?

When will Moderna release Q2 earnings?

Moderna is scheduled to release second quarter earnings before US markets open on Wednesday August 3. The company will hold a conference call on the same day at 0800 ET.

Moderna Q2 earnings consensus

Wall Street forecasts revenue will drop 7.6% in the second quarter to $4.0 billion and diluted EPS is expected to plunge 30% to $4.54.

Moderna Q2 earnings preview

Moderna is expected to report the first drop in sales since it started making serious sums selling its Covid-19 vaccine when it reports second quarter results this week.

Hype around Covid-19 vaccine makers has waned this year as the pandemic has eased, and the attention will remain on how demand is shaping up and whether governments are still committed to jabbing against sub-variants. Investors will be hopeful it can reiterate its guidance to strike signed purchase agreements worth $21 billion in 2022.

Moderna has said it expects to secure slightly more orders in the second half compared to the first. The company has only announced one major new deal since its last set of results, having agreed to sell 66 million doses of its vaccine to the US government as it continues with its booster programme. That is worth some $1.74 billion, and the government has an option to purchase another 234 million doses which, based on the price of the initial round of jabs, could be worth another $6.2 billion. That will provide some confidence that governments remain committed to jabbing their populations.

While the focus remains on its Covid-19 drug, it is hoping to release up to three respiratory drugs in the next two to three years if everything goes to plan. A new vaccine targeting the BA.4/5 sub-variant is on its way, although this could cause softness in the meantime if buyers decide to wait for the new jab.

Markets remain uncertain what this year will hold for Moderna. Wall Street’s revenue forecasts remain wide for 2022, ranging from a low of $20.3 billion to a high of $25.9 billion (with a mean of $22.0 billion). Diluted EPS is forecast to dip 2.9% in 2022 following the landmark profit made last year, which was the first it has recorded since inception.

Where next for MRNA stock?

Moderna shares were thrusted into overbought territory after hitting its highest level in over two months at $176 last month, suggesting this could be a tough ceiling to crack for the stock. The fact trading volumes over the last 10 sessions are almost half the 100-day average supports the view that it could struggle to break above this level without a new catalyst. If it can, then the March-high of $188 comes into view, followed by the 200-day moving average at $193. Notably, the 20 brokers that cover the stock see slightly more upside potential with an average target price of $221, where it last sat in early 2022.

On the downside, the 50-day and 100-day moving averages that have converged around the $150 mark can be treated as an initial floor for the stock going forward, although we could see it falter back toward $120 if it comes under renewed pressure. The 18-month low of $116 should be regarded as the ultimate floor.

How to trade Moderna stock

You can trade Moderna shares with City Index in just four easy steps:

Open a City Index account, or log-in if you’re already a customer.
Search for ‘Moderna’ in our award-winning platform
Choose your position and size, and your stop and limit levels
Place the trade

Or you can try out your trading strategy risk-free by signing up for our Demo Trading Account.

This report is intended for general circulation only. It should not be construed as a recommendation, or an offer (or solicitation of an offer) to buy or sell any financial products. The information provided does not take into account your specific investment objectives, financial situation or particular needs. Before you act on any recommendation that may be contained in this report, independent advice ought to be sought from a financial adviser regarding the suitability of the investment product, taking into account your specific investment objectives, financial situation or particular needs.

StoneX Financial Pte. Ltd., may distribute reports produced by its respective foreign entities or affiliates within the StoneX group of companies or third parties pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed to a person in Singapore who is not an accredited investor, expert investor or an institutional investor (as defined in the Securities Futures Act), StoneX Financial Pte. Ltd. accepts legal responsibility to such persons for the contents of the report only to the extent required by law. Singapore recipients should contact StoneX Financial Pte. Ltd. at 6826 9988 for matters arising from, or in connection with the report.

In the case of all other recipients of this report, to the extent permitted by applicable laws and regulations neither StoneX Financial Pte. Ltd. nor its associated companies will be responsible or liable for any loss or damage incurred arising out of, or in connection with, any use of the information contained in this report and all such liability is hereby expressly disclaimed. No representation or warranty is made, express or implied, that the content of this report is complete or accurate.

StoneX Financial Pte. Ltd. is not under any obligation to update this report.

Trading CFDs and FX on margin carries a high level of risk that may not be suitable for some investors. Consider your investment objectives, level of experience, financial resources, risk appetite and other relevant circumstances carefully. The possibility exists that you could lose some or all of your investments, including your initial deposits. If in doubt, please seek independent expert advice. Visit www.cityindex.com/en-sg/terms-and-policies for the complete Risk Disclosure Statement.

ALL TRADING INVOLVES RISKS. LOSSES CAN EXCEED DEPOSITS.

City Index is a trading name of StoneX Financial Pte. Ltd. (“SFP”) for the offering of dealing services in Contracts for Differences (“CFD”). SFP holds a Capital Markets Services Licence issued by the Monetary Authority of Singapore for Dealing in Exchange-Traded Derivatives Contracts, Over-the-Counter Derivatives Contracts, and Spot Foreign Exchange Contracts for the Purposes of Leveraged Foreign Exchange Trading. SFP is also both Derivatives Trading and Clearing member of the Singapore Exchange (“SGX”). SFP is a wholly-owned subsidiary of StoneX Group Inc.

The information provided herein is intended for general circulation. It does not take into account the specific investment objectives, financial situation or particular needs of any particular person. You should take into account your specific investment objectives, financial situation or particular needs before making a commitment to invest, including seeking advice from an independent financial adviser regarding the suitability of the investment, under a separate engagement, as you deem fit. No representation or warranty is given as to the accuracy or completeness of this information. Consequently, any person acting on it does so entirely at their own risk.

The information does not represent an offer of, or solicitation for, a transaction in any investment product. Any views and opinions expressed may be changed without an update. To understand the risks and costs involved, please visit the section captioned “Important Information” and the “Risk Disclosure Statement”.

The information herein is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation.

StoneX Financial Pte. Ltd. 1 Raffles Place, #18-61, One Raffles Place Tower 2, Singapore 048616. Tel: 6309 1000. Co. Reg. No.: 201130598R.

This advertisement has not been reviewed by the Monetary Authority of Singapore.